Zealand Deals Diabetes Drug to Aventis
Executive Summary
Denmark's Zealand Pharma inked its second Big Pharma deal in as many months when it out-licensed its lead product, a Phase II diabetes treatment, to Aventis. Zealand's accelerated development of the product--which was tested immediately in patients, bypassing healthy volunteers--provided the firm with clinical proof of prinicple, on a budget.You may also be interested in...
Gastrotech Pharma AS
Roche Signs Up Ipsen--Again
BioVitrum/Amgen: A Sign of Early-Stage Deals to Come
Need a specific report? 1000+ reports available
Buy Reports